Literature DB >> 8121613

Intracerebral 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists.

J P Tizzano1, K I Griffey, J A Johnson, A S Fix, D R Helton, D D Schoepp.   

Abstract

The functional role of metabotropic glutamate receptor (mGluR) activation was investigated following intracerebral administration of 1S,3R-ACPD in mice. Injections of 1S,3R-ACPD (50-800 nmol in 5 microliters) into the thalamus produced a dose-dependent increase in limbic seizures. These effects were stereoselective since 1R,3S-ACPD, did not elicit seizure activity. Pharmacologically, limbic seizures were attenuated by the mGluR partial agonist/antagonist L-2-amino-3-phosphonopropionate (L-AP3) and dantrolene, an inhibitor of intracellular calcium mobilization, but not by D-AP3 or ionotropic glutamate receptor antagonists (MK-801 or GYKI-52466). Thus, activation of mGluRs by 1S,3R-ACPD in mice, induces limbic seizures that may involve the mobilization of intracellular calcium stores.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8121613     DOI: 10.1016/0304-3940(93)90548-y

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Status epilepticus-induced alterations in metabotropic glutamate receptor expression in young and adult rats.

Authors:  E M Aronica; J A Gorter; M C Paupard; S Y Grooms; M V Bennett; R S Zukin
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

Review 2.  Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.

Authors:  Susanne Muehlschlegel; John R Sims
Journal:  Neurocrit Care       Date:  2008-08-12       Impact factor: 3.532

3.  Therapeutic potential of metabotropic glutamate receptor modulators.

Authors:  N Hovelsø; F Sotty; L P Montezinho; P S Pinheiro; K F Herrik; A Mørk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.